Unity of explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
Paragraph 12 is the last paragraph of the Pharmaceutical Patent Guidelines (October 2014) and deals with unity of invention. It tells examiners how to decide whether the claims of a drug application relate to one inventive concept or to several, with worked examples for claims that lack unity from the start, claims that lack it only after the prior art is found, mixed claim categories, Markush groups and intermediates.
The claims must relate to a single invention or to a group linked by a single inventive concept (12.1). The link is a special technical feature, a common technical relationship that is inventive over the prior art (12.3). Unity can fail a priori (the claims share no structural feature) or a posteriori (the shared feature is already in the prior art). Markush alternatives need a common property and a significant common structure (12.9), and an intermediate and a final product must be technically closely interrelated (12.12). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from October 2014. The remedy for a unity objection is usually a divisional application; since 2024 the rules have changed in this area, and our posts on rule 13 and divisional applications and on sections 16 and 17 should be read for the position as now in force. The Manual's treatment is in our article on Manual Chapter 6 and on sufficiency and unity. If a unity objection has already been raised, a patent objection reply is the next step.
The rule and the test (paragraphs 12.1 to 12.4)
Section 10(5) requires the claims to relate to a single invention or to a group of inventions linked so as to form a single inventive concept. The Guidelines quote the Manual's advice that, although the number of claims is not limited, it is advisable to limit the claims and independent claims so that they are of cognate character, and that a plurality of distinct inventions may be objected to for lack of unity.
The test is that every claim should share a single common technical relationship that is inventive: the special technical feature. It is determined from the claims supported by the description, in light of the prior art. Pharmaceutical applications often combine Markush structures, intermediates and final products, compositions, processes, uses and sometimes apparatus, which makes search and examination hard; the paragraph exists to guide that.
Lack of unity a priori (paragraph 12.5)
A priori means the lack is visible without a prior art search. The Guidelines' example is three claims to three unrelated compounds (an antibiotic, a steroid and a bioactive compound) all for treating the same infection. They share no common structural feature that could unify them, so each is a separate invention. A shared use is not a shared structure.
Lack of unity a posteriori (paragraph 12.6)
A posteriori means the lack appears after the prior art is found. In the example, one claim covers a combination of a sulphonamide compound with a taxane and another covers the same compound with a vinca alkaloid derivative, for cancer. The prior art already teaches the sulphonamide for cancer. The two partner agents are structurally different, so the only common element is already known, and so it is not a special technical feature. The groups lack unity a posteriori.
The Guidelines describe the special technical feature as an essential structural part common to all embodiments, responsible for the inventive effect and absent in the prior art that gives the same solution.
Different categories of claims (paragraph 12.7)
| Example in the Guidelines | Unity? | Reason |
|---|---|---|
| A compound, a method of preparing it, and the compound for use as a fungicide | Yes | The special technical feature is the compound |
| A process of manufacture with steps A and B, and two apparatus claims, one designed for A and one for B | Process and either apparatus: yes. The two apparatus claims together: no | No common special technical feature between the two apparatus claims |
| A compound, a process for it with step A, and an apparatus designed for step A | Yes, if the compound is new | The process must result in the compound and the apparatus's contribution must match the process's inventive feature; if the compound is known, there is no common special technical feature |
Markush claims (paragraphs 12.8 to 12.10)
Unity is met where the alternatives are of a similar nature: they share a common property or activity, and a significant common structural element. That includes compounds sharing a common structure that occupies a large portion of each, or only a small portion that is structurally distinctive in view of the prior art and essential to the common property.
- Passes: compounds of the general form R1-R2-R3 with an indolyl group fixed at R1 and methyl, benzyl or phenyl elsewhere, all useful for asthma. A significant structural element is shared and the activity is common.
- Fails: the same form with R1 defined as a heterocyclic group covering a huge range of unrelated molecular species. They cannot be structurally linked, so they do not fall within a single inventive concept.
Intermediates and final products (paragraphs 12.11 to 12.19)
An intermediate is a starting or intermediate product that is used in a process to produce the final product through a change in which its identity is lost. Unity between an intermediate and a final product needs both conditions:
- the same essential structural element, or technically closely interrelated structures, with the intermediate incorporating an essential structural element into the final product; and
- a technical interrelationship, meaning the final product is made directly from the intermediate or through a small number of intermediates that all share the essential element.
The Guidelines add six more rules.
| Paragraph | Rule |
|---|---|
| 12.14 | If either structure is unknown, there must be sufficient evidence that they are technically closely interrelated |
| 12.15 | Different intermediates used in different processes to make the final product have unity if they share the same essential structural element |
| 12.16 | The intermediate and final product must not be separated by an intermediate that is not new |
| 12.17 | Different intermediates for different structural parts of the final product do not have unity |
| 12.18 | Where both are families of compounds, each intermediate must correspond to a compound in the family of final products |
| 12.19 | Other properties or activities of the intermediates do not affect unity |
Two examples are given, one where the structures are closely interrelated and one where the intermediate is an open ring precursor of the final product. In both unity is found.
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Do all independent claims share a special technical feature? | A common structure or step that is new over the prior art |
| Does the shared feature survive the prior art? | That the common element is not already known, or a different inventive link |
| Are the Markush alternatives of a similar nature? | Common property and a significant common structure or distinctive portion |
| Is each intermediate linked to the final product? | The essential structural element that passes into the final product, and a short synthetic path |
| Are there apparatus claims? | That each apparatus is specially designed for a step of the claimed process, and the process leads to the claimed product |
How a unity objection is usually answered
- Show the link. Identify the special technical feature that joins the claims and explain why it is inventive over the prior art.
- Narrow. Limit the Markush group or remove an independent claim to restore unity.
- Divide. Where the groups are genuinely distinct, file a divisional for the remaining group, following the rules in force.
The Act and Rules as now in force prevail on the form, time and conditions for a divisional; read the rule post before relying on any period.
A worked example (invented)
Navjeevan Pharma files claims to a compound X, to a composition of X with a vasodilator and to a composition of X with a diuretic. The compound X is new. The examiner raises lack of unity. Navjeevan answers that the compound X is the special technical feature common to all three claims, being new and giving the inventive effect, and the combination claims depend on it. The Guidelines' reasoning for the a posteriori example turns the other way when the shared compound is already known; because X is new here, the objection should be withdrawn.
Common lapses
- Claiming several unrelated compounds for the same use and calling the use the link.
- Relying on a shared component that is already known.
- Drafting a Markush group around a very wide heterocyclic group.
- Including apparatus claims for steps that have nothing in common with each other.
Need help with a unity of invention objection?
Unity objections are answered most effectively by showing the link, narrowing the claims or dividing the application, and the right choice depends on the prior art and the commercial value of each group. Our team can advise and prepare the filings. See patent objection reply, and read the preceding article on sufficiency, clarity and support.
Key takeaways
- Claims must be linked by a special technical feature that is inventive over the prior art.
- Unity can fail a priori, with no shared structure, or a posteriori, with a known shared feature.
- Markush alternatives need a common property and a significant common structure.
- Intermediates and final products need closely interrelated structures and a short path.
- The Act and Rules as now in force prevail on divisional filing.
Read next
- Pharmaceutical Patent Guidelines 2014, paragraph 11: sufficiency, clarity and support
- Manual Chapter 6: divisional applications and patents of addition
- Manual Chapter 9: sufficiency of disclosure and unity of invention
- Sections 16 and 17 of the Patents Act, 1970: division of application
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.